Psoriatic Arthritis

Changes in BMI were positively correlated with changes in IL-23 and significant positive correlations were observed between BMI and DAS28-CRP, CRP, IL-13, IL-17, leptin, and TNF-α.

Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.

In the updated analysis, the interleukin-23 p19-subunit inhibitor also showed better skin efficacy.

Women with psoriatic arthritis reported higher mean pain and worse mean patient global assessment when compared with men.

In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs.

At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.

Etanercept was effective at 6 months of follow-up and remained so at 12 months, with low rates of adverse events.

Serum levels of BD-2 at baseline were shown to be significantly linked with subsequent clinical response in patients with psoriatic arthritis.

Celastrol may regulate core target proteins to alleviate the inflammatory response.

Guselkumab was able to provide minimal disease activity improvements from baseline through week 48 in adult patients with psoriatic arthritis.

Patients with unrestful sleep had significantly reduced health-related quality of life and significantly more depressive symptoms.

While most patients were interested in an online wellness program for managing their psoriatic arthritis, barriers, such as cost and fatigue, hindered their initiation of lifestyle adaptations.

More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.

Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.

An analysis of data from the phase 4 MOSAIC trail is providing clinicians with a greater understanding of the effects of apremilast in people with uncontrolled psoriatic arthritis.

An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.

New data from EULAR 2023 offers a comparison of the levels of vascular inflammation among patients with psoriatic arthritis relative to healthy controls.

Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.

Janssen's efforts are accompanied by extensive data generation in patients of color and the creation of a diverse workforce.

Janssen aims to address health inequities and promote culturally competent care.

Patients with higher platelet or neutrophil counts or platelet/lymphocyte ratios and systemic immune/inflammation index scores were more resistant to conventional systemic agents.

Statistically significant improvements were observed in all 10 PROMIS domains analyzed.

An analysis of patient-reported outcomes data from more than 15,000 people with rheumatic disease sheds light on the apparent differences in impact on quality of life between psoriatic arthritis and rheumatoid arthritis.

The analyses emphasized the early and sustained resolution of enthesitis through 52 weeks with both adalimumab and secukinumab.

Leveraging data from the 2020 UPLIFT survey, investigators offer an overview of the quality of life and treatment satisfaction among people with psoriasis and psoriatic arthritis in the US.

At the 2-year mark after methotrexate initiation, 71% of patients with psoriatic arthritis and 76% of patients with rheumatoid arthritis remained on methotrexate.

An analysis of the Clinical Practice Research Datalink provides an overview of trends and prevalence of long-term opioid use among patients with 1 of 6 rheumatic or musculoskeletal diseases using 3 definitions of long-term opioid use.

In addition to demonstrating efficacy, the numbers and incidence rates of treatment-emergent adverse events and treatment-emergent infections decreased throughout the 10-year follow-up.

Sustained low disease activity/remission was associated with functional and health-related quality of life improvements.